Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease
Terminated
- Conditions
- Renal Cell CarcinomaHypertensionMelanomaCancer
- Registration Number
- NCT03709771
- Lead Sponsor
- Vanderbilt University Medical Center
- Brief Summary
The purpose of this study is to understand the effect of vascular endothelial growth factor tyrosine kinase (VEGF) inhibitor, immune checkpoint-inhibitor (ICI), and combination treatment on blood pressure and blood vessel function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 2
Inclusion Criteria
- Male or female, age 40 - 75 years old
- Diagnosis of cancer
- Receiving VEGF inhibitor, ICI, or combination (VEGF inhibitor + ICI or combination ICI) treatment, or not receiving any treatment.
- Normal blood pressure or blood pressure treated to < 140/90 mm Hg with ≤2 antihypertensive medications
Exclusion Criteria
- Presence of peripheral artery disease
- History of a heart attack within 1 year
- History of a stroke within 1 year
- Diabetes
- Life expectancy < 3 months
- Women who are pregnant
- Women who are nursing
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in Mean Blood Pressure Baseline and 1 month Mean 24 hour blood pressure from ambulatory 24 hour recording
- Secondary Outcome Measures
Name Time Method Ratio of Post-treatment to Pre-treatment Change in Digital Pulse Amplitude Baseline and 1 month Digital pulse amplitude will be measured using peripheral artery tonometry
Trial Locations
- Locations (1)
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center🇺🇸Nashville, Tennessee, United States